{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:41:16Z","timestamp":1792550476267,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T00:00:00Z","timestamp":1467676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T00:00:00Z","timestamp":1467676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1038\/pcan.2016.26","type":"journal-article","created":{"date-parts":[[2016,7,5]],"date-time":"2016-07-05T10:21:14Z","timestamp":1467714074000},"page":"380-384","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?"],"prefix":"10.1038","volume":"19","author":[{"given":"L E","family":"Howard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"De Hoedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W J","family":"Aronson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C J","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C L","family":"Amling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M R","family":"Cooperberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M K","family":"Terris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C H","family":"Divers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S J","family":"Freedland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,5]]},"reference":[{"key":"BFpcan201626_CR1","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","volume":"61","author":"MM Center","year":"2012","unstructured":"Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61: 1079\u20131092.","journal-title":"Eur Urol"},{"key":"BFpcan201626_CR2","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nrclinonc.2011.67","volume":"8","author":"J Sturge","year":"2011","unstructured":"Sturge J, Caley MP, Waxman J . Bone metastasis in prostate cancer: emerging therapeutic strategies. Nat Rev Clin Oncol 2011; 8: 357\u2013368.","journal-title":"Nat Rev Clin Oncol"},{"key":"BFpcan201626_CR3","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502\u20131512.","journal-title":"N Engl J Med"},{"key":"BFpcan201626_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424\u2013433.","journal-title":"N Engl J Med"},{"key":"BFpcan201626_CR5","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458\u20131468.","journal-title":"J Natl Cancer Inst"},{"key":"BFpcan201626_CR6","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdu519","volume":"26","author":"MR Smith","year":"2015","unstructured":"Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol 2015; 26: 368\u2013374.","journal-title":"Ann Oncol"},{"key":"BFpcan201626_CR7","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"CJ Logothetis","year":"2012","unstructured":"Logothetis CJ, Basch E, Molina A, Fizazi K, North SA, Chi KN et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13: 1210\u20131217.","journal-title":"Lancet Oncol"},{"key":"BFpcan201626_CR8","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S1470-2045(14)70303-1","volume":"15","author":"K Fizazi","year":"2014","unstructured":"Fizazi K, Scher HI, Miller K, Basch E, Sternberg CN, Cella D et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014; 15: 1147\u20131156.","journal-title":"Lancet Oncol"},{"key":"BFpcan201626_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fossa SD et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013; 369: 213\u2013223.","journal-title":"N Engl J Med"},{"key":"BFpcan201626_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M Norgaard","year":"2010","unstructured":"Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT . Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010; 184: 162\u2013167.","journal-title":"J Urol"},{"key":"BFpcan201626_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/pcan.2011.7","volume":"14","author":"N Sathiakumar","year":"2011","unstructured":"Sathiakumar N, Delzell E, Morrisey MA, Falkson C, Yong M, Chia V et al. Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006. Prostate Cancer Prostatic Dis 2011; 14: 177\u2013183.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201626_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.jgo.2014.03.002","volume":"5","author":"E Onukwugha","year":"2014","unstructured":"Onukwugha E, Yong C, Mullins CD, Seal B, McNally D, Hussain A . Skeletal-related events and mortality among older men with advanced prostate cancer. J Geriatr Oncol 2014; 5: 281\u2013289.","journal-title":"J Geriatr Oncol"},{"key":"BFpcan201626_CR13","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1634\/theoncologist.2015-0327","volume":"21","author":"JA McDougall","year":"2016","unstructured":"McDougall JA, Bansal A, Goulart BH, McCune JS, Karnopp A, Fedorenko C et al. The clinical and economic impacts of skeletal-related events among medicare enrollees with prostate cancer metastatic to bone. Oncologist 2016; 21: 320\u2013326.","journal-title":"Oncologist"},{"key":"BFpcan201626_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/pcan.2015.25","volume":"18","author":"DM Moreira","year":"2015","unstructured":"Moreira DM, Howard LE, Sourbeer KN, Amarasekara HS, Chow LC, Cockrell DC et al. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2015; 18: 333\u2013337.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"BFpcan201626_CR15","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1200\/JCO.2011.35.8648","volume":"29","author":"HI Scher","year":"2011","unstructured":"Scher HI, Morris MJ, Basch E, Heller G . End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. J Clin Oncol 2011; 29: 3695\u20133704.","journal-title":"J Clin Oncol"},{"key":"BFpcan201626_CR16","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.juro.2008.01.040","volume":"179","author":"RJ Hamilton","year":"2008","unstructured":"Hamilton RJ, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL et al. Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. J Urol 2008; 179: 1785\u20131790.","journal-title":"J Urol"},{"key":"BFpcan201626_CR17","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1001\/jama.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433\u2013439.","journal-title":"JAMA"},{"key":"BFpcan201626_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12874-015-0047-5","volume":"15","author":"A Aly","year":"2015","unstructured":"Aly A, Onukwugha E, Woods C, Mullins CD, Kwok Y, Qian Y et al. Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods. BMC Med Res Methodol 2015; 15: 65.","journal-title":"BMC Med Res Methodol"},{"key":"BFpcan201626_CR19","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Damiao R, Brown J, Karsh L et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813\u2013822.","journal-title":"Lancet"},{"key":"BFpcan201626_CR20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2015","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 2015; 387: 1163\u20131177.","journal-title":"Lancet"},{"key":"BFpcan201626_CR21","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1111\/j.1464-410X.2008.08283.x","volume":"103","author":"S Oudard","year":"2009","unstructured":"Oudard S, Banu E, Medioni J, Scotte F, Banu A, Levy E et al. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int 2009; 103: 1641\u20131646.","journal-title":"BJU Int"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/pcan201626.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201626","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/pcan201626.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T21:09:27Z","timestamp":1648674567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pcan201626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,5]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["BFpcan201626"],"URL":"https:\/\/doi.org\/10.1038\/pcan.2016.26","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,5]]},"assertion":[{"value":"8 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}